Feeley Kevin 4

What Happened

• Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), had 717 restricted stock units (RSUs) settle on June 1, 2026 (converted to 717 shares at $0.00 per share) and sold 369 shares in an open-market "sell-to-cover" transaction at $51.74 each, generating $19,092. The filings show both the RSU settlement (derivative exercise/conversion) and the open-market sale.

Key Details

• Transaction date: June 1, 2026.
• RSU settlement: 717 shares acquired upon conversion (exercise/conversion code M) at $0.00 (footnote F1: RSUs settle for no consideration).
• Open-market sale: 369 shares disposed at $51.74 each, proceeds $19,092 (code S). Footnote F2: the sale was a sell-to-cover to satisfy tax withholding obligations and not a discretionary sale by the reporting person.
• Additional derivative entry: 717 shares listed as disposed at $0.00 (reflecting RSU settlement/withholding mechanics).
• Shares/holdings after the transaction (per filing): 35,290 shares of Class A common stock beneficially owned, plus RSUs representing rights to up to 91,702 shares and options to purchase up to 25,906 shares (footnote F3).
• Vesting note: the RSU award vests quarterly at 6.25% per tranche with the first tranche vested Dec 1, 2022 (footnote F4).
• Filing: reported on Form 4 filed June 3, 2026 (transactions dated June 1, 2026); no late-filing indication in the report.

Context

• This activity appears to be a routine sell-to-cover tied to the automatic settlement of RSUs to satisfy tax withholding. The RSUs were converted/settled (no purchase price), and a portion of shares was sold rather than paid in cash for taxes. Such sell-to-cover transactions are common and do not necessarily indicate an executive view on the company’s stock price.